Figure S1. Study designs.

Figure S2. Mean and 95% CI of relative (%) reduction in seizure frequency over the 12-week maintenance period (ITT and PP populations).

Figure S3. Mean end/start of treatment ratio and 95% CI of trough (Cmin) plasma concentrations of most frequency used concomitant AEDs, carbamazepine, lamotrigine and valproic acid.

Table S1. Main baseline characteristics of study population.

Table S2. ANCOVA of seizure frequency per 4 weeks over the 12-week maintenance period (ITT and PP populations).

Table S3. Summary of treatment-emergent adverse events (TEAEs) (safety populations).

Table S4. Time to onset of treatment-emergent adverse events (TEAEs).

epi3605_sm_FigS1.tif267KSupporting info item
epi3605_sm_FigS2.tif105KSupporting info item
epi3605_sm_FigS3.tif144KSupporting info item
epi3605_sm_TableS1-S3.docx51KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.